Netflix Doesn't Need to Worry About Amazon or Hulu
More and more Americans are subscribing to multiple streaming services.
The Most Important Chart for Chipotle Mexican Grill
Current and prospective investors in Chipotle should keep a close eye on its same-store sales.
Have Investors Been Overlooking Ulta Beauty Inc?
Brick-and-mortar retail stocks haven't been too popular lately. Here are a few reasons to get excited about this beauty products and salon chain again.
5 Things PepsiCo's Management Wants You to Know
Here are five key quotes from the soda and snack food giant's second-quarter earnings call.
Should investors continue holding Amazon if the eight-year old bull market abruptly ends?
Two of the pipeline builder’s largest projects hit roadblocks this week, which could spell more trouble down the road.
Automotive and industrial computing sales are booming, so TI is paying more taxes than usual. Nice problem, right?
Despite good news for much of the stock market, these stocks fell. Find out why.
Multiple catalysts are driving the cloud leader's share price higher.
These stocks played a major role in pushing markets higher. Find out why.
After a solid second quarter, management lays out plans for future growth.
Strong fiscal 2016 growth, analyst upgrades, and iPhone component speculation have fueled Himax's share-price growth this year.
Bempedoic acid could cut bad cholesterol in a big way and could be up for approval as early as 2019.
Wall Street never likes it if a company doesn't meet expectations, even if those expectations may be out of line with the business.
YouTube better watch out.
Two quarterly earnings beats have been more than enough to push up the company's share price this year.
These three ETFs could be a great way for you to stay in, or enter, the market.
Government reimbursement rates may slip 0.4% in 2018, and that's pressuring stocks across the home healthcare industry.
The home robotics specialist just announced a stellar quarter and increased its guidance. Here's what investors need to know.
Here's everything investors need to know heading into Take-Two's quarterly release.
Looking for relatively safer picks during a market meltdown? Check out Colgate-Palmolive, McCormick & Company, and Enbridge.
Investors should hold onto this high-quality growth story.
The executive behind the most commonly used Alzheimer's drug is working on a follow-up that will be used in combination.